Latanoprost/Timolol Maleate

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") in Portugal, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative medicine for the treatment of inflammation and pain following ocular surgery. DÁVI is a trusted partner of Pharmathen Global Holding B.v., AZAD Pharma AG, NTC S.r.l. and Pfizer through marketing and promotion of Xalacom© (Latanoprost + Timolol) and Xalatan© (Latanoprost) for more than 12 years. DÁVI is one of the key players in the Portuguese Market, with over 100 years' history in the distribution and promotion of branded ophthalmology products. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024, was recently launched in the United States in September, 2024. The DÁVI licensing agreement includes upfront, commercialization milestones, and sales milestones, with additional considerations throughout the term of the agreement. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. In a recent survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007. APP13007 anticipates significant potential in Portugal, which has around 90,000 cataract surgeries, annually, as reported by Eurostat. "This partnership with DÁVI Farmacêutica, marks our first entry into a competitive EU market, opening the door for growth into other EU territories. DÁVI's experience and commitment to novel ophthalmic therapies is steadily apparent and Formosa Pharma appreciates their recognition of APP13007 as a worthy offering to patients recovering from ocular surgery." said Erick Co, President and CEO of Formosa Pharmaceuticals. Rui Alves, Business Development Manager of DÁVI Farmacêutica, stated, "We are excited at DÁVI to be partnering with Formosa and have the opportunity to offer this cutting-edge drug and technology to our ophthalmologists and patients, reinforcing our strong position in the market and the commitment to enhance the well-being of our people." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit . About DÁVI Farmacêutica DÁVI Farmacêutica, is a century-old company and one of the key players in ophthalmology and ENT segments in Portugal. The company's core activities are the distribution & promotion of branded medicines with significant partnerships with major multinational pharmaceutical companies. Our daily mission is to give our patients the best option available in the market, making their lives better. To know more about DÁVI Farmacêutica, visit . SOURCE Formosa Pharmaceuticals Inc., WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

June 27, 2016 By Mark Terry , BioSpace.com Breaking News Staff Arguing The Case for Pfizer Buying Amgen Is Pfizer considering buying Amgen ? Although BidnessEtc writes today about how a good fit it would be, given a number of factors, so far nothing official along those lines have been announced. In April, Pfizer called off its plans to merge with Dublin-based Allergan , largely due to new U.S. Treasury rules aimed at curbing tax inversion deals. This prompted numerous analysts to speculate on what companies Pfizer might acquire. At the same time, even during the Pfizer-Allergan prenuptial planning, divorce was already in the cards, as the company was also planning to split the merged company into two units. One would focus on newer, faster-growing drugs and the other would focus on mature slow-growth products. Aliya Kaleem , writing for BidnessEtc, points out that Pfizer has been in a slow process of restructuring for some time, starting with the sale in 2012 of its nutritional products division to Nestle . Then it spun off its animal health unit, Zoetis , as a separate company in January 2013. This was followed by a failed inversion merger with AstraZeneca in 2014, then Allergan. “Pfizer has been reporting declining sales since the past few years, as some of its top revenue generating products lost their patents, landing a dent on the company’s revenues,” writes Kaleem. “Some of the items to contribute to the sales decline include Lipitor, Celebrex, and Xalatan/Xalacom.” The plans to split Pfizer appear to still be on the table, although to what extent is largely unknown. When the Allergan deal collapsed, Pfizer’s chief executive officer, Ian Read, said, “We plan to make a decision about whether to pursue a potential separation of our innovative and established businesses by no later than the end of 2016, consistent with our original timeframe for the decision prior to the announcement of the potential Allergan transaction.” That would, according to Kaleem, mean Pfizer splitting off its Global Established Products (GEP) business. This is also called Pfizer Essential Health , and is made up of established and off-patent drugs. Pfizer would then be made up of two other major business segments, Global Innovation Products (GIP), and Vaccines Oncology and Consumer (VOC). GIP includes drugs such as Lyrica, Enbrel, Xeljanz, and Eliquis, which brought in $3.6 billion in this year’s first quarter alone. GIP projections for 2016 are $14.6 billion. VOC brought in $3.4 billion in this year’s first quarter, or about 29 percent of total company revenues. The primary driver was Prevnar, a vaccine, and Ibranc, an oncology drug. Projections are it will have $14.7 billion in sales this year. GEP had sales of $5.9 billion in the first quarter, or about 45 percent of total revenues. Projections are it will hit $23.4 billion this year. Kaleem writes, “The declining revenue from all three units suggests that the company needs a strategic acquisition, which would boost all of the units. This target might be hard to acquire, but there are a few options which would fit into the separate units well, thereby pushing the growth rates.” Which is where Amgen fits in, assuming it fits in at all. The company has annual revenue of close to $22 billion. Its older drugs include Enbrel, Neupogen, Neulasta and Epogen. They are near patent expiration, which would fit with Pfizer’s GEP. Otherwise, Amgen has a strong and growing oncology portfolio, including Xgeva, Prolia, Kyprolis, Vectibix, and Blincyto. These are expected to drive company revenues and would be a good fit with Pfizer’s VOC unit. And Amgen’s cardiology and metabolic drugs would fit reasonably well with Pfizer’s GIP division. Pfizer has about $13 billion in cash, and Amgen stock has dropped almost 7 percent this year. Amgen is currently trading for $145.64 per share. Pfizer is trading for $33.71. Pfizer recently completed its acquisition of Anacor Pharmaceuticals . Maybe Amgen is next.